Compare Amgen, Inc. (AMGN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Under Armour Inc Class A — how do they compare? Amgen, Inc. trades at $412.15 (market cap $224.14B), while Under Armour Inc Class A trades at $5.24 (market cap $2.26B). The key difference: Amgen, Inc. is far larger — about 99.2× Under Armour Inc Class A's market cap, and Amgen, Inc. pays a 2.43% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| AMGN | UA | |
|---|---|---|
Market Cap | $224.14B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $7.88 |
52-Week Low | $271.18 | $3.96 |
Enterprise Value | $267.45B | $3.24B |
Dividend Yield | 2.43% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
